Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Journal of Pharmacology

• Publication date

  2006-01-20

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.EJPHAR.2005.11.038PMID 16403499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment Published, JLR Papers in Press, July 16, 2004. DOI 10.1194/jlr.M400220-JLR200

  2004cited by this paper
• Inhibition of Glucosylceramide Synthase Does Not Reverse Drug Resistance in Cancer Cells*

  2004cited by this paper
• Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling.

  2004cited by this paper
• Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.

  2004cited by this paper
• Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.

  2003cited by this paper
• CHAPTER 22 – LIPID TRANSPORT BY ABC TRANSPORTERS

  2003cited by this paper
• ABC proteins : from bacteria to man

  2003cited by this paper
• Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins.

  2002cited by this paper
• Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis

  2002cited by this paper
• Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists.

  2001cited by this paper
• Principles of Clinical Pharmacology

  2001cited by this paper
• The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence

  2001cited by this paper
• Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis

  2000cited by this paper
• Lipid Traffic: The ABC of Transbilayer Movement

  2000cited by this paper
• Retroviral Transfection of Madin-Darby Canine Kidney Cells with Human MDR1 Results in a Major Increase in Globotriaosylceramide and 105- to 106-Fold Increased Cell Sensitivity to Verocytotoxin

  2000cited by this paper
• N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.

  2000cited by this paper
• Improved Inhibitors of Glucosylceramide Synthase*

  1999influential reference
• The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein

  1999influential reference
• The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter.

  1999cited by this paper
• Prevalence of lysosomal storage disorders.

  1999cited by this paper
• Glucosylceramide: a marker for multiple-drug resistant cancers.

  1998cited by this paper
• The multi‐drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P‐glycoprotein by an allosteric interaction

  1997cited by this paper
• Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance.

  1996cited by this paper
• Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane.

  1995cited by this paper
• Pharmacological characterization of N-substituted phenoxazines directed toward reversing Vinca alkaloid resistance in multidrug-resistant cancer cells.

  1993cited by this paper
• The nitrogen of the acetamido group of colchicine modulates P-glycoprotein-mediated multidrug resistance.

  1993cited by this paper
• Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties.

  1993cited by this paper
• Modulation of cell-surface transferrin receptor by the imino sugar N-butyldeoxynojirimycin.

  1992cited by this paper
• Improved inhibitors of glucosylceramide synthase.

  1992cited by this paper
• Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.

  1990cited by this paper
• Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.

  1989cited by this paper
• Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.

  1986cited by this paper
• Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

  1978cited by this paper
• Active amino acid transport in plasma membrane vesicles from Simian virus 40-transformed mouse fibroblasts. Characteristics of electrochemical Na+ gradient-stimulated uptake.

  1977cited by this paper
• The constitution and fundamental properties of solids and liquids. Part II.—Liquids

  1917cited by this paper
• THE CONSTITUTION AND FUNDAMENTAL PROPERTIES OF SOLIDS AND LIQUIDS

  year unknowncited by this paper

• Alteration of ceramide 1-O-functionalization as a promising approach for cancer therapy.

  2012cites this paper
• The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function.

  2011cites this paper
• Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.

  2009cites this paper
• Synthesis of the naringinase inhibitors l-swainsonine and related 6-C-methyl-l-swainsonine analogues: (6R)-C-methyl-l-swainsonine is a more potent inhibitor of l-rhamnosidase by an order of magnitude than l-swainsonine

  2008cites this paper
• Looking glass inhibitors: synthesis of a potent naringinase inhibitor l-DIM [1,4-dideoxy-1,4-imino-l-mannitol], the enantiomer of DIM [1,4-dideoxy-1,4-imino-d-mannitol] a potent α-d-mannosidase inhibitor

  2007cites this paper